(i) a first anti-cancer agent, which is BVD-523 or a pharmaceutically acceptable salt thereof and (ii) a second anti-cancer agent, which is an epidermal growth factor receptor (EGFR) inhibitor or a pharmaceutically acceptable salt thereof, to treat or ameliorate the effects of the cancer. ...
产品名称:ERK Inhibitor 产品别名: CAS号:1049738-54-6 英文别名:ERK Inhibitor 分子量:328.8 分子式:C14H16N2O3S ? HCl 纯度:≥95% 外观:见爱必信官网 保存方法:Store at -20℃,2 years. 描述:ERK inhibitor is a cell-permeable inhibitor that binds ERK2 near its docking domain (KD = 5 µM...
Cancer Discov. 2, 685–693 (2012). Article CAS Google Scholar Infante, J. R. et al. A randomised, double-blind, placebo-controlled trial of trametinib, an oral MEK inhibitor, in combination with gemcitabine for patients with untreated metastatic adenocarcinoma of the pancreas. Eur. J. ...
Dietary interventions such as intermittent fasting (IF) have emerged as an attractive strategy for cancer therapies; therefore, understanding the underlying molecular mechanisms is pivotal. Here, we find SIRT7 decline markedly attenuates the anti-tumor e
ERK-IN-2 是ERK2抑制剂探针,IC50值为 1.8 nM。 ERK-IN-2 的使用剂量 >10 μM 可能导致脱靶毒性和/或脱靶活性。 ERK-IN-2Chemical Structure *Please selectQuantitybefore adding items. 所有产品仅用作科学研究或药证申报,我们不为任何个人用途提供产品和服务...
ERK1/2 inhibitor 1 是一种有效的,口服生物可利用的 ERK1/2 抑制剂,在 1 nM 时抑制 ERK1 达60%,抑制 ERK2 的 IC50 为3.0 nM。 ERK1/2 inhibitor 1 Chemical Structure CAS No. : 2095719-90-5 规格价格是否有货数量 5 mg ￥6500 In-stock 10 mg ￥9800 In-stock 50 mg ￥25500 In-stock...
Discovery of a novel ERK inhibitor with activity in models of acquired resistance to BRAF and MEK inhibitors Cancer Discov., 3 (2013), pp. 742-750 View in ScopusGoogle Scholar 53 S. Jha, E.J. Morris, A. Hruza, M.S. Mansueto, G.K. Schroeder, J. Arbanas, D. McMasters, C.R. Re...
Both claudin-2 and p-ERK1/2 levels were decreased by EGF neutralizing antibody, EGF receptor (EGFR) siRNA, AG1478, an inhibitor of EGFR, U0126, an inhibitor of MEK, and the exogenous expression of dominant negative-MEK. These results suggest that EGF is secreted from A549 cells by MMP ...
Mice were subcutaneously implanted with 1.5 × 105 CT26 cells and treated with control vehicle, USP5 inhibitor (EOAI3402143), MEK inhibitor (Trametinib), or combined treatment, respectively. b, c The growth of CT26 tumors in BALB/c mice with indicated treatments (b). Kaplan–Meier ...
Bottom panel: densitometric analysis of the western blotting shown in the upper panel, reporting the percentage of P-FAKSer732 respect to total FAK upon inhibitor treatments. Error bars, S.D. (b) Upper panel: western blotting performed on lysates from Me#28 cells transfected with control- (CO...